Metabolic safety of antihypertensive drugs: myth versus reality (Q36590829)

15 August 2017

1 reference

title

Metabolic safety of antihypertensive drugs: myth versus reality (English)

1 reference

15 August 2017

Sameer Stas

1

1 reference

PubMed ID

16965727

15 August 2017

Lama Appesh

series ordinal

2

1 reference

PubMed ID

16965727

15 August 2017

James Sowers

series ordinal

3

1 reference

15 August 2017

1 October 2006

1 reference

Current Hypertension Reports

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

5

1 reference

15 August 2017

403-408

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-006-0086-8

15 August 2017

0 references

cites work

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-006-0086-8

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-006-0086-8

Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-006-0086-8

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

12 December 2020

Insulin resistance and cardiovascular disease

1 reference

12 December 2020

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

12 December 2020

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression

1 reference

12 December 2020

Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).

1 reference

12 December 2020

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

1 reference

12 December 2020

Pathogenesis of hypertension in diabetes

1 reference

12 December 2020

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

1 reference

12 December 2020

Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus

1 reference

12 December 2020

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

12 December 2020

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

12 December 2020

Insulin resistance and hypertension

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

New-onset diabetes and antihypertensive drugs

1 reference

12 December 2020

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

12 December 2020

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

12 December 2020

Antihypertensive drugs and insulin resistance in obesity.

1 reference

12 December 2020

When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk

1 reference

12 December 2020

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

1 reference

12 December 2020

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

1 reference

12 December 2020

Are beta blockers passé for the treatment of hypertension?

1 reference

12 December 2020

Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group

1 reference

12 December 2020

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

1 reference

12 December 2020

Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels

1 reference

12 December 2020

The key role of insulin resistance in the cardiometabolic syndrome

1 reference

12 December 2020

Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

1 reference

12 December 2020

1 reference

12 December 2020

Glucose metabolism in patients with essential hypertension.

1 reference

12 December 2020

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

12 December 2020

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

12 December 2020

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications

1 reference

12 December 2020

Beta-adrenergic blocking agents in patients with diabetes-- friend and foe

1 reference

12 December 2020

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

1 reference

12 December 2020

Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome

1 reference

12 December 2020

Antihypertensive therapy and the risk of type 2 diabetes mellitus

1 reference

12 December 2020

Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study

1 reference

12 December 2020

Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial.

1 reference

12 December 2020

Antihypertensive therapy and incidence of type 2 diabetes: a systematic review

1 reference

12 December 2020

Development of diabetes with thiazide diuretics: the potassium issue

1 reference

12 December 2020

10.1007/S11906-006-0086-8

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16965727